The play-the-winner (PW) rule is an important method in clinical trials where patients can be assigned to one of the two treatments. In the PW rule, the probability of the next patient to be assigned to a particular treatment only depends on the response of the current patient. In this paper, we consider a general kind of PW rule for multi-treatment adaptive designs, in which the probability that a treatment is assigned to the next patient depends upon both the response of the previous patient and an estimated parameter, e.g., the observed success rate. Using this kind of adaptive designs, more information of previous stages are used to update the model at each stage, and more patients may be assigned to better treatments. The strong consistency and the asymptotic normality are established for the allocation proportions.
Introduction
In comparing treatments 1 and 2 with dichotomous response (success and failure), suppose subjects arrive to the experiment sequentially and must be assigned immediately to treatment 1 or 2. Zelen [18] proposed the well-known play-the-winner (PW) rule: a success on a particular treatment generates a future trial on the same treatment with a new patient. A failure on a treatment generates a future trial on the alternate treatment. The PW rule is used for the ethical consideration in which more patients are assigned to a better treatment. As an extension of PW rule, Wei and Durham [17] proposed the randomized play-the-winner (RPW) rule based on the urn model. Wei [16] extended the RPW rule to multi-treatment clinical trials. And he also defined a generalized Polya's urn (GPU) design. The asymptotic properties of the RPW rule and its various generalizations to multi-treatment cases based on the GPU have been studied by many authors (cf., [16, 14, 13, 2, 3] , etc.). Recently, Bai et al. [4] proposed a new adaptive design for multi-arm clinical trials. In this adaptive design, the urn is updated according to the rate of sample's success. Such design can assign more patients to better treatments than Wei's does. However, the asymptotic distribution of the allocation proportion is unknown.
When the cure rate of each treatment is large (close to 1), the asymptotic distribution of the allocation proportion is unknown in using the RPW rule or its generalizations to multitreatment cases based on the GPU. The variability of the RPW rule and the GPU model is very high unless all treatments have low cure rates. The variability of allocation may have a strong effect on the power. This has been demonstrated by the simulation studies of Melfi and Page [9] as well as Rosenberger et al. [12] , and Hu and Rosenberger [8] . Due to the unknown distribution and high variability, the designs in which we use urn models become less applicable when the treatments have high cure rates, in sense that it is difficult to test whether or not a design truly assign more patients to better treatments or the design fit the desirable goals.
In this paper, we consider an alternative generalization of the PW rule and define a new adaptive design. In this new adaptive design, instead of using the urn model, we assign each patient directly with a certain probability that depends on an estimated parameter, e.g., the observed success rate. A special case (see Example 2.1) of this new adaptive design is similar to the one proposed by Bai et al. [4] . However, the asymptotic normality holds now in almost all cases. Another special case (see Example 2.3) is the sequential maximum likelihood procedure mentioned by Melfi and Page [9, 10] and Melfi et al. [11] . In Section 2, we define the new design and give some examples. The asymptotic properties, including the strong consistency and its convergence rate, the asymptotic normality and Gaussian approximation are discussed in Section 3. The technical proofs are given in Section 4.
The design and examples
Consider a d-treatment clinical trial. Patients are recruited to the clinical trial sequentially and can respond immediately to treatments. Suppose at stage m, the mth patient is assigned to treatment i. We write the response of the mth patient to treatment i as m,i , which is a random variable following the distribution P i , where i ∈ i . Then the (m + 1)th patient will be assigned to treatment j according to a certain probability, which depends on the response m,i of the mth patient. Let d ij ( m,i ) denote this probability. After n assignments, let N ni be the number of patients assigned to treatment i, for i = 1, . . . , d, and let X ni = 1 if the nth patient is assigned to treatment i and 0 otherwise. Write N n = (N n1 , . . . , N nd ), X n = (X n1 , . . . , X nd ) and = ( 1 , . . . , d ). It is obvious that N n 1 = N n1 +· · ·+N nd = n, where 1 = (1, . . . , 1). Also,
Such a design is a generalization of the two-treatment Markov chain adaptive design proposed by Bai et al. [1] . We write m = ( m,1 , . . . , m,d ), and assume that { m , m = 1, 2, . . .} is a sequence of i.i.d. random vectors. In the clinical trial, i,k is observed when the ith patient is assigned to treatment k, i.e., X i,k = 1. The complete data consist of all the responses
In many cases, the parameters k 's can be regarded as rules to measure whether a treatment is good or not. If 1 , . . . , d are known, it is reasonable to use them to optimize the design. In such case, the assignment probability d ij depends on , i.e.,
and then
It follows that {X n ; n 1} is a homogeneous Markov chain with transition matrix
However, the parameter is usually unknown and needs to be estimated. Now let us consider the following adaptive design. Throughout this paper, we assume that = E m . Then we can use the sample mean to estimate . 
Now, if the mth patient is assigned to treatment i and the response is observed, then we assign the (m + 1)th patient to treatment j with probability d ij (ˆ m−1 , m,i ), j = 1, . . . , d. However, to insure that each treatment is tested by enough patients, i.e., N ni → ∞ a.s.,
1)
Here F n = (X 1 , . . . , X n , 1 , . . . , n−1 ) is the history sigma field. We also let h ij ( m−1 ) Usually, many cases, in which the parameter is not a mean of the response n , can be transferred to the case we have studied above. In fact, if for each k, the estimator n,k = n,k ( j,k : j = 1, 2, . . . , n) of can be written in the following form:
3)
then in the Adaptive Design 1, we can define m−1,k = n,k ( j,k : X j,k = 1, j = 1, 2, . . . , m − 1).
Many maximum likelihood estimators and moment estimators satisfy (2.3).
As a function of , H( ) is assumed to be continuous at , i.e., H(x) → H = H( ) as x → . It is obvious that H1 = 1 . So, 1 = 1 is an eigenvalue of H. Let 2 , . . . , d be other d − 1 eigenvalues of H, and let = max{| 2 |, . . . , | d |}. Then 1. Also, we let v = (v 1 , . . . , v d ) be a left eigenvector of H corresponding to its maximal eigenvalue 1 = 1 with v1 = 1 and v i 0, i = 1, . . . , d. Such an eigenvector according to the matrix theory is unique when i = 1 , i = 2, . . . , d. In the next section, we will claim that under some suitable conditions (stated in Section 3) on the function H(·) and moments of the responses, N n n → v a.s. and
Next, we give some examples of the special case that the treatments have dichotomous outcomes, the success and failure. Consider that the patient is assigned to treatment k, let p k be the probability of success, and q k = 1 − p k , for k = 1, . . . , d. We assume that 0 < p k < 1, for k = 1, . . . , d. As an extension of the PW rule to the multi-treatment case, Hoel and Sobel [6] proposed the cyclic play-the-winner (PWC) rule: if the response on treatment k is a success, we assign the next patient to the same treatment. If the response is a failure, we assign the next patient to the treatment k + 1. Here, treatment d + 1 means treatment 1. By using the PWC rule, one has
The PWC rule can make more patients to undergo better treatments. However, one may argue, when there is a failure on treatment k, why we assign the next patient to treatment k+1 instead of any other treatment or some of the d −1 treatments with certain probabilities. When there is a failure on treatment k, it should be more reasonable to assign the next patient with higher probability to a better treatment among the other d − 1 treatments. Motivated by this, we will consider the following adaptive design.
Example 2.1. If the response on treatment k is a success, we assign the next patient to the same treatment. If the response is a failure, we assign the next patient to other d−1 treatments with probabilities proportional to the estimated rate of success, i.e., at stage m, when the response of the mth patient on treatment k is a failure, we assign the (m + 1)th patient to
N m−1,j +1 , and S m−1,j denotes the number of successes of treatment j in all the N m−1,j trials of previous m − 1 stages, j = 1, . . . , d. For this design, we have
The next example is an extension of Example 2.1.
At the mth stage, if the response is a failure, we assign the 
and v (0) i =:
By comparing the values of v ( ) 's, one can find the larger . Then more patients will be assigned to a better treatment. It is obvious that v
Hence, the design in Examples 2.1 or 2.2 can assign more patients to better treatments than the PWC rule can. Also, when there is a failure, the assignment is random in the designs defined in these two examples. Hence, these designs are not so deterministic as the PWC rule. [4] proposed a design similar to that in Examples 2.1. But for the GPU model, to study the asymptotic normality, we need a very stringent condition, that is, max{Re( 2 ), . . . , Re( d )} 1/2. Even in the three-treatment case, such a condition is not easy to check.
Finally we give an example for the two-treatment case. Example 2.3. We consider the two-treatment adaptive design. At the mth stage, no matter what the response of the mth patient is, we assign the (m + 1)th patient to treatment j with probabilityq m−1,ĵ q m−1,1 +q m−1,2 , j = 1, 2. This is the sequential maximum likelihood procedure proposed by Melfi and Page [9, 10] and Melfi et al. [11] . If 0 < p 1 , p 2 < 1, then
We have the following asymptotic properties:
= O log log n n a.s. and
This design gives the same limiting proportions as the PW rule does.
Asymptotic properties
To study the precise asymptotic properties, we first need some assumptions. H(x) , we assume that for some > 0,
Using the notation and assumptions defined as above, we can now establish the following results. The next theorem gives us the strong approximation of N n . . . . , f d ) ,
Then possibly in a richer underlying probability space in which there exist two independent d-dimensional standard Brownian motions {B t } and {W t }, we can redefine the sequence {X n , n } without changing its distribution, such that
3)
for some > 0. In particular, = ( f 1 , . . . , f d ) . 
Proofs
We start with some lemmas that will be used to prove the strong consistency and its convergence rate. 
Then, { m,k , m = 1, 2, . . .} is a sequence of i.i.d. random variables, with the same distribution as that of 1,k (cf., [4] ). Also, n,k = 
Proof. For each fixed k, it is obvious that
which implies that P(X m,k = 1, i.o.) = 1 by the generalized Borel-Cantelli lemma (cf., [5] ). It follows that N n,k → ∞ a.s. If (2.2) is satisfied, then the proof is similar.
Proof of Theorem 3.1.
Write
From (2.1), it follows that
i.e.,
where e i is a vector whose ith component is 1 and other components are 0, i = 1, . . . , d. It follows that:
So, {X m } looks like a non-homogeneous Markov chain with transition matrix H n . Let Z n = X n − E[X n |F n−1 ], and M n = n k=1 Z n . By (4.1), it is easily seen that
It follows that
On the other hand, it is obvious that Z n 2. By the law of the iterated logarithm for martingales (cf., [ Now, we begin the proof of Theorem 3.3. Recall (4.2), in which the martingale M n can be approximated by a Wiener process. If the term n k=1 X k (H k − H) is asymptotically negligible, the Gaussian approximation of N n can be gotten easily. However, by (4.5), the fastest convergence rate of n k=1 X k (H k −H) is O( √ n log log n). So we shall do something else to deal with this term. At first, we will give the other three lemmas. The first one shows that n k=1 X k (H k − H) can be approximated by n k=1 v(H k − H).
Proof. Without loss of generality, we can assume that x is the Euclidean norm of x, ∀x ∈ R d , and M = sup x =0 xM / x is the norm of a d × d matrix M. Write H 0 = e 1 EX 1 . For k 0, let X k = EX 1 , H k = H 0 , F k = F 0 and Z k = 0. Then, for p n 1,
Observe that X j 1 = 1, Z j 1 = 0, H j − 1 v = (H − 1 v) j = H j and (H j − H)1 = 1 − 1 = 0. We have
We conclude that n k=1
Notice that lim j →∞ H j 1/j = | | < 1. So, for | | < < 1, there exists a constant C > 0 such that H j C j , j 0. It follows that
and
Substituting (4.9)-(4.12) into (4.7) and letting p → ∞ yields (4.6).
The next two lemmas are related to the strong approximation for a martingale. Suppose that there exists a constant 0 < < 1 such that
Furthermore, suppose T is a covariance matrix measurable with respect to F k for some k 0. Then for any > 0, possibly in a richer underlying probability space in which there exists a K-dimensional standard Brownian {B t }, we can redefine the sequence {S n } and T, without changing their distributions, such that {B t } is independent of T, and
for some > 0. Here n = max m n T m − mT .
Proof. This lemma is proved by [19] , we omit the details here.
Suppose that Assumption 3.2 is satisfied. Then for any > 0, there are two independent d-dimensional standard Brownian motions B t and W t and a positive number > 0, such that 
Also, by noting that Q n = O √ n log log n a.s., n,k = n m=1 X m,k m,k +1 N n,k +1
, k = 1, . . . , d, and (3.1), we have 
The proof is now completed.
A Note on the Proof of Example 2.3. Write E = (1, −1) (1, −1). Note that v 1 = q 2 q 1 +q 2 , v 2 = q 1 q 1 +q 2 , 2 1 = p 1 q 1 , 2 2 = p 2 q 2 ,
So, H = H − 1 v = 0 and = 1 = q 1 q 2 (q 1 +q 2 ) 2 E. Also, *H(x) *x 1 x=(p 1 ,p 2 ) = q 2 (q 1 + q 2 ) 2 1 −1 1 −1 and *H(x) *x 2 x=(p 1 ,p 2 )
The proof is completed.
